Share

 
 

Want information on dosing?

Reimbursement & patient access?

See our Approved Products

Related Resources for this page:

Obinutuzumab (GA101)

GA101 is a type II, glycoengineered, humanized anti-CD20 monoclonal antibody designed to bind with high affinity and selectivity to the extracellular domain of CD20 on the surface of B cells. Binding of GA101 leads to higher cell death induction in malignancies with CD20 positive B-cells.1-3 This agent is being investigated in collaboration with Biogen Idec.

GA101
Click here to view a larger version of this image

By virtue of its type II antibody characteristics, GA101 causes higher direct cell death induction of cancer cells and lower complement recruitment compared with type I anti-CD20 antibodies.2 Modification of sugars to the Fc region of GA101 (GlycoMAb™ technology) has resulted in stronger binding to immune-effector cells, which translates to enhanced ADCC.2,3

Preclinical studies demonstrate that GA101 induces significant B-cell depletion in peripheral blood as well as in lymphoid tissue. It also mediates high antitumor activity in preclinical NHL studies, both as a single agent and in conjunction with chemotherapy.1

  1. GA101 is the first type II glycoengineered anti-CD20 monoclonal antibody.1,2

    B-cell GA101 Vignette 1

  2. Preclinical studies have shown that because of its type II mode of binding to the extracellular domain of CD20, GA101 substantially increases direct cell death induction.2

    B-cell GA101 Vignette 2

  3. Glycoengineering of the GA101 molecule enables it to bind with higher affinity to immune effector cells, such as natural killer cells, which bind and target the tumor cells for destruction.3

    B-cell GA101 Vignette 3

References:
1.
Friess T, Herting F, Bauer S, et al. GA101, a novel therapeutic type II CD20 antibody with outstanding efficacy and clear superiority in subcutaneous non-Hodgkin lymphoma xenograft models as well as superior B cell depletion. Presented at: American Association for Cancer Research; April 12-16, 2008; San Diego, CA. Abstract 4012.
2.
Nopora A, Preiss S, Nicolini V, et al. Contribution of enhanced ADCC to superior in vivo efficacy of the novel type II humanized, third generation CD20 antibody GA101 in NHL xenograft models. Presented at: American Association for Cancer Research; April 12-16, 2008; San Diego, CA. Abstract 3991.
3.
Umana P, Moessner E, Bruenker P, et al. Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. Blood. 2006;108. Abstract 229.